AnaptysBio Stock Price, News & Analysis (NASDAQ:ANAB)

$114.91 4.46 (4.04 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$114.91
Today's Range$110.66 - $116.26
52-Week Range$15.17 - $116.67
Volume385,803 shs
Average Volume257,775 shs
Market Capitalization$2.60 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About AnaptysBio (NASDAQ:ANAB)

AnaptysBio logoAnaptysBio, Inc. is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANAB
CUSIPN/A
Phone858-362-6295

Debt

Debt-to-Equity Ratio0.09%
Current Ratio10.77%
Quick Ratio10.77%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.68 million
Price / Sales161.89
Cash FlowN/A
Price / CashN/A
Book Value($2.00) per share
Price / Book-57.46

Profitability

Trailing EPSN/A
Net Income$-4,250,000.00
Net MarginsN/A
Return on Equity-39.38%
Return on Assets-24.95%

Miscellaneous

Employees49
Outstanding Shares23,500,000

AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How were AnaptysBio's earnings last quarter?

AnaptysBio Inc (NASDAQ:ANAB) posted its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.02. View AnaptysBio's Earnings History.

Where is AnaptysBio's stock going? Where will AnaptysBio's stock price be in 2018?

8 equities research analysts have issued twelve-month price objectives for AnaptysBio's shares. Their predictions range from $76.00 to $144.00. On average, they anticipate AnaptysBio's share price to reach $99.13 in the next twelve months. View Analyst Ratings for AnaptysBio.

Are investors shorting AnaptysBio?

AnaptysBio saw a increase in short interest in the month of December. As of December 29th, there was short interest totalling 1,387,012 shares, an increase of 40.3% from the December 15th total of 988,390 shares. Based on an average trading volume of 280,607 shares, the days-to-cover ratio is currently 4.9 days. Approximately 9.8% of the shares of the stock are sold short.

Who are some of AnaptysBio's key competitors?

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the folowing people:

  • Hamza Suria, President, Chief Executive Officer, Director (Age 40)
  • Dominic G. Piscitelli, Chief Financial Officer (Age 42)
  • Marco Londei M.D., Chief Medical Officer (Age 60)
  • Hollings C. Renton III, Lead Independent Director (Age 70)
  • Carol G. Gallagher, Independent Director (Age 52)
  • Nicholas B. Lydon Ph.D., Independent Director (Age 60)
  • John P. Schmid, Independent Director (Age 53)
  • James A. Schoeneck, Independent Director (Age 59)

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns AnaptysBio stock?

AnaptysBio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.32%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier, Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio.

Who bought AnaptysBio stock? Who is buying AnaptysBio stock?

AnaptysBio's stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. Company insiders that have bought AnaptysBio stock in the last two years include Healthcare Vii LP Frazier and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio.

How do I buy AnaptysBio stock?

Shares of AnaptysBio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AnaptysBio's stock price today?

One share of AnaptysBio stock can currently be purchased for approximately $114.91.

How big of a company is AnaptysBio?

AnaptysBio has a market capitalization of $2.60 billion and generates $16.68 million in revenue each year. AnaptysBio employs 49 workers across the globe.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]


MarketBeat Community Rating for AnaptysBio (ANAB)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AnaptysBio (NASDAQ:ANAB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $99.13$89.75$77.67$35.60
Price Target Upside: 10.25% downside2.40% downside11.67% upside46.62% upside

AnaptysBio (NASDAQ:ANAB) Consensus Price Target History

Price Target History for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2018Robert W. BairdReiterated RatingBuy$81.00 -> $144.00HighView Rating Details
12/18/2017Royal Bank of CanadaBoost Price TargetOutperform$108.00MediumView Rating Details
11/15/2017SunTrust BanksInitiated CoverageBuy -> Buy$115.00N/AView Rating Details
11/9/2017Jefferies GroupInitiated CoverageBuy -> Buy$101.00N/AView Rating Details
11/7/2017WedbushReiterated RatingOutperform -> Positive$75.00 -> $82.00N/AView Rating Details
10/13/2017Stifel NicolausReiterated RatingBuy$35.00 -> $76.00N/AView Rating Details
10/10/2017Credit Suisse GroupBoost Price TargetOutperform$38.00 -> $85.00N/AView Rating Details
10/10/2017JMP SecuritiesBoost Price TargetOutperform$45.00 -> $82.00N/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

AnaptysBio (NASDAQ:ANAB) Earnings History and Estimates Chart

Earnings by Quarter for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ ANAB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.47)($0.45)$2.78 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.42)($0.13)$3.45 million$7.00 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.18)($0.75)$1.63 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AnaptysBio (NASDAQ:ANAB) Earnings Estimates

2018 EPS Consensus Estimate: ($1.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.51)($0.24)($0.39)
Q2 20183($0.64)($0.33)($0.47)
Q3 20183($0.72)($0.37)($0.53)
Q4 20183($0.80)($0.40)($0.58)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for AnaptysBio (NASDAQ:ANAB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AnaptysBio (NASDAQ ANAB) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 75.48%
Insider Trades by Quarter for AnaptysBio (NASDAQ:ANAB)
Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ ANAB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/21/2017Holdings A/S NovoMajor ShareholderSell356,300$21.10$7,517,930.001,936,604View SEC Filing  
8/15/2017Holdings A/S NovoMajor ShareholderSell178,600$21.16$3,779,176.002,436,332View SEC Filing  
8/7/2017Holdings A/S NovoMajor ShareholderSell491,294$21.12$10,376,129.282,952,527View SEC Filing  
8/3/2017Holdings A/S NovoMajor ShareholderSell70,706$23.31$1,648,156.863,009,949View SEC Filing  
7/26/2017Ventures Vii L P AvalonMajor ShareholderSell37,040$24.35$901,924.00View SEC Filing  
1/31/2017Healthcare Vii L.P. FrazierMajor ShareholderBuy400,000$15.00$6,000,000.00View SEC Filing  
1/31/2017Nicholas LydonDirectorBuy16,666$15.00$249,990.00270,957View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AnaptysBio (NASDAQ ANAB) News Headlines

Source:
DateHeadline
AnaptysBios (ANAB) "Buy" Rating Reaffirmed at Robert W. BairdAnaptysBio's (ANAB) "Buy" Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - January 20 at 4:50 PM
AnaptysBio Inc (ANAB) Expected to Post Quarterly Sales of $2.10 MillionAnaptysBio Inc (ANAB) Expected to Post Quarterly Sales of $2.10 Million
www.americanbankingnews.com - January 15 at 4:42 PM
AnaptysBio Inc (ANAB) Sees Significant Increase in Short InterestAnaptysBio Inc (ANAB) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 14 at 2:32 AM
AnaptysBio Inc (ANAB) Expected to Post Earnings of -$0.43 Per ShareAnaptysBio Inc (ANAB) Expected to Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - January 13 at 9:26 AM
AnaptysBio (ANAB) Cut to "Hold" at Zacks Investment ResearchAnaptysBio (ANAB) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 2 at 5:56 PM
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and CalyxtThe Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt
finance.yahoo.com - January 2 at 10:30 AM
Strange: Bullish ANAB Analysts Actually See -17.88% DownsideStrange: Bullish ANAB Analysts Actually See -17.88% Downside
www.nasdaq.com - January 1 at 4:15 PM
AnaptysBio Inc (ANAB) Receives Average Recommendation of "Buy" from BrokeragesAnaptysBio Inc (ANAB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 1 at 1:56 AM
5 Best Performing IPOs of 20175 Best Performing IPOs of 2017
finance.yahoo.com - December 29 at 4:14 PM
Royal Bank of Canada Increases AnaptysBio (ANAB) Price Target to $108.00Royal Bank of Canada Increases AnaptysBio (ANAB) Price Target to $108.00
www.americanbankingnews.com - December 18 at 11:46 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Amgen, Alexion Pharma, AnaptysBio, and Akcea TherapeuticsQuotidian Technical Highlights on Selected Biotech Stocks -- Amgen, Alexion Pharma, AnaptysBio, and Akcea Therapeutics
www.bizjournals.com - December 14 at 10:50 AM
Head to Head Review: Opexa Therapeutics (ACER) & AnaptysBio (ANAB)Head to Head Review: Opexa Therapeutics (ACER) & AnaptysBio (ANAB)
www.americanbankingnews.com - December 10 at 9:36 AM
AnaptysBio Inc (ANAB) Receives Average Recommendation of "Buy" from AnalystsAnaptysBio Inc (ANAB) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 7 at 1:46 AM
AnaptysBio Sees Unusually High Options Volume (ANAB)AnaptysBio Sees Unusually High Options Volume (ANAB)
www.americanbankingnews.com - December 2 at 1:10 AM
AnaptysBio (ANAB) and Nivalis Therapeutics (ALPN) Head-To-Head SurveyAnaptysBio (ANAB) and Nivalis Therapeutics (ALPN) Head-To-Head Survey
www.americanbankingnews.com - November 21 at 5:38 AM
AnaptysBio, Inc. (ANAB) Now Covered by Analysts at SunTrust Banks, Inc.AnaptysBio, Inc. (ANAB) Now Covered by Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - November 19 at 4:56 PM
Brokers Set Expectations for AnaptysBio, Inc.s FY2017 Earnings (ANAB)Brokers Set Expectations for AnaptysBio, Inc.'s FY2017 Earnings (ANAB)
www.americanbankingnews.com - November 17 at 9:44 PM
Wedbush Brokers Boost Earnings Estimates for AnaptysBio, Inc. (ANAB)Wedbush Brokers Boost Earnings Estimates for AnaptysBio, Inc. (ANAB)
www.americanbankingnews.com - November 13 at 3:58 AM
AnaptysBio, Inc. (ANAB) to Post FY2017 Earnings of ($1.65) Per Share, Jefferies Group ForecastsAnaptysBio, Inc. (ANAB) to Post FY2017 Earnings of ($1.65) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 13 at 3:58 AM
AnaptysBio, Inc. (ANAB) Given Consensus Rating of "Buy" by BrokeragesAnaptysBio, Inc. (ANAB) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 12 at 1:50 AM
AnaptysBio, Inc. (ANAB) Upgraded by Zacks Investment Research to "Hold"AnaptysBio, Inc. (ANAB) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - November 10 at 3:42 PM
Brokers Issue Forecasts for AnaptysBio, Inc.s FY2019 Earnings (ANAB)Brokers Issue Forecasts for AnaptysBio, Inc.'s FY2019 Earnings (ANAB)
www.americanbankingnews.com - November 9 at 3:40 PM
AnaptysBio, Inc. (ANAB) Rating Reiterated by WedbushAnaptysBio, Inc. (ANAB) Rating Reiterated by Wedbush
www.americanbankingnews.com - November 7 at 11:16 AM
AnaptysBio, Inc. (ANAB) Posts  Earnings ResultsAnaptysBio, Inc. (ANAB) Posts Earnings Results
www.americanbankingnews.com - November 7 at 11:15 AM
Anaptysbio (ANAB) Announces Positive ANB019 Top-line Phase 1 Clinical Trial ResultsAnaptysbio (ANAB) Announces Positive ANB019 Top-line Phase 1 Clinical Trial Results
www.streetinsider.com - November 7 at 2:57 AM
AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial ResultsAnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results
finance.yahoo.com - November 6 at 4:40 PM
AnaptysBio to Participate in Upcoming Investor ConferencesAnaptysBio to Participate in Upcoming Investor Conferences
finance.yahoo.com - October 31 at 5:08 PM
AnaptysBio, Inc. (ANAB) Receives Consensus Recommendation of "Buy" from AnalystsAnaptysBio, Inc. (ANAB) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 18 at 4:52 AM
Anaptysbio (ANAB) Prices 3M Share Common Offering at $68.50/ShAnaptysbio (ANAB) Prices 3M Share Common Offering at $68.50/Sh
www.streetinsider.com - October 14 at 8:46 PM
AnaptysBio, Inc. (ANAB) Receives Buy Rating from Stifel NicolausAnaptysBio, Inc. (ANAB) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - October 13 at 11:56 PM
AnaptysBio, Inc. (ANAB) Stock Rating Reaffirmed by WedbushAnaptysBio, Inc. (ANAB) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - October 13 at 11:20 PM
Q1 2018 EPS Estimates for AnaptysBio, Inc. (ANAB) Cut by AnalystQ1 2018 EPS Estimates for AnaptysBio, Inc. (ANAB) Cut by Analyst
www.americanbankingnews.com - October 13 at 11:10 AM
AnaptysBio Announces Pricing of Public OfferingAnaptysBio Announces Pricing of Public Offering
finance.yahoo.com - October 12 at 9:44 PM
Featured Company News - AnaptysBio Announces Positive Interim Data from Phase-2a Clinical Trial of ANB020 for Treating Atopic DermatitisFeatured Company News - AnaptysBio Announces Positive Interim Data from Phase-2a Clinical Trial of ANB020 for Treating Atopic Dermatitis
finance.yahoo.com - October 12 at 4:42 PM
AnaptysBio Reaches Analyst Target PriceAnaptysBio Reaches Analyst Target Price
www.nasdaq.com - October 11 at 5:25 PM
AnaptysBio Inc. (ANAB) Soared To A New High On Phase 2 Study ResultsAnaptysBio Inc. (ANAB) Soared To A New High On Phase 2 Study Results
www.rttnews.com - October 11 at 5:25 PM
AnaptysBio, Inc. (ANAB) Downgraded by Zacks Investment ResearchAnaptysBio, Inc. (ANAB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 11 at 5:20 PM
AnaptysBios (ANAB) Positive Rating Reaffirmed at Robert W. BairdAnaptysBio's (ANAB) Positive Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - October 11 at 10:18 AM
Royal Bank Of Canada Raises AnaptysBio, Inc. (ANAB) Price Target to $79.00Royal Bank Of Canada Raises AnaptysBio, Inc. (ANAB) Price Target to $79.00
www.americanbankingnews.com - October 10 at 7:04 PM
Credit Suisse Group Boosts AnaptysBio, Inc. (ANAB) Price Target to $85.00Credit Suisse Group Boosts AnaptysBio, Inc. (ANAB) Price Target to $85.00
www.americanbankingnews.com - October 10 at 7:04 PM
Pre-Open Movers 10/10: (KALV) (ANAB) (VICL) Higher; (JBL) (LLY) (AXTA) Lower (more...)Pre-Open Movers 10/10: (KALV) (ANAB) (VICL) Higher; (JBL) (LLY) (AXTA) Lower (more...)
www.streetinsider.com - October 10 at 5:13 PM
Why AnaptysBio Is One of Tuesday’s Top StocksWhy AnaptysBio Is One of Tuesday’s Top Stocks
247wallst.com - October 10 at 5:13 PM
AnaptysBio Inc. (ANAB) Has Soared To A New High On Phase 2 Study ResultsAnaptysBio Inc. (ANAB) Has Soared To A New High On Phase 2 Study Results
www.nasdaq.com - October 10 at 5:13 PM
AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic DermatitisAnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis
finance.yahoo.com - October 10 at 5:13 PM
Here's Why AnaptysBio Inc. Is Rocketing Higher TodayHere's Why AnaptysBio Inc. Is Rocketing Higher Today
finance.yahoo.com - October 10 at 5:13 PM
AnaptysBio Files Registration Statement for Proposed Public OfferingAnaptysBio Files Registration Statement for Proposed Public Offering
finance.yahoo.com - October 10 at 5:13 PM
This Biotech Hit Record High; Could Undercut Regeneron In EczemaThis Biotech Hit Record High; Could Undercut Regeneron In Eczema
finance.yahoo.com - October 10 at 5:13 PM
JMP Securities Raises AnaptysBio, Inc. (ANAB) Price Target to $82.00JMP Securities Raises AnaptysBio, Inc. (ANAB) Price Target to $82.00
www.americanbankingnews.com - October 10 at 4:34 PM
Head to Head Comparison: Omeros Corporation (OMER) versus AnaptysBio (ANAB)Head to Head Comparison: Omeros Corporation (OMER) versus AnaptysBio (ANAB)
www.americanbankingnews.com - October 7 at 4:18 AM
ETFs with exposure to AnaptysBio, Inc. : October 2, 2017ETFs with exposure to AnaptysBio, Inc. : October 2, 2017
finance.yahoo.com - October 2 at 3:43 PM

SEC Filings

AnaptysBio (NASDAQ:ANAB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AnaptysBio (NASDAQ:ANAB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AnaptysBio (NASDAQ ANAB) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.